The DOI matches its Crossref record.
Physiological Parameters in Laboratory Animals and Humans
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The extrapolated time-zero plasma radioactivity (Q0) is an underestimate because the calculated plasma volume of distribution (17.6 ml) is much greater than the plasma volume reported for the rats of this size, i.e. ~12.5 ml [Davies and Morris 1993]”
From Clearance kinetics of the VGF-derived neuropeptide TLQP-21 (2018) · cites this paper as Davies and Morris 1993
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Cited by
Matute-Bello, G., Downey, G., Moore, B. B., Groshong, S. D., Matthay, M. A., Slutsky, A. S., & Kuebler, W. M. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0210st · Cited by 1,988
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Physiological Parameter Values for Physiologically Based Pharmacokinetic Models
Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997) · Toxicology and Industrial Health · doi:10.1177/074823379701300401 · Cited by 1,415
Wu, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080771 · Cited by 1,030
“91 mL/100 g/mL, but it is about 750 mL/100 g/mL in a typical human muscle [52].”
BackgroundThe Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Welsher, K., Sherlock, S. P., & Dai, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014501108 · Cited by 958
Rodgers, T., & Rowland, M. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20502 · Cited by 946
Pharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation
Irie, T., & Uekama, K. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960213f · Cited by 924
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Stella, V. J., & He, Q. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310945 · Cited by 700
Li, B., Lu, L., Zhao, M., Lei, Z., & Zhang, F. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201801226 · Cited by 658
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
On The Rate and Extent of Drug Delivery to the Brain
Hammarlund-Udenaes, M., Fridén, M., Syvänen, S., & Gupta, A. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9502-2 · Cited by 513
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205854200 · Cited by 508
Bridging solubility between drug discovery and development
Di, L., Fish, P. V., & Mano, T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.007 · Cited by 491
A microfluidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip
Sung, J. H., Kam, C., & Shuler, M. L. (2010) · Lab on a Chip · doi:10.1039/b917763a · Cited by 484
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
Cancer as a metabolic disease: implications for novel therapeutics
Seyfried, T. N., Flores, R. E., Poff, A. M., & D'Agostino, D. P. (2014) · Carcinogenesis · doi:10.1093/carcin/bgt480 · Cited by 472
Programmable probiotics for detection of cancer in urine
Danino, T., Prindle, A., Kwong, G. A., Skalak, M., Li, H., Allen, K., Hasty, J., & Bhatia, S. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3519 · Cited by 467
Obach, R. S., Lombardo, F., & Waters, N. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020479 · Cited by 462
Kelley, S. K., Harris, L. A., Xie, D., DeForge, L., Totpal, K., Bussiere, J., & Fox, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 445
Sung, J. H., & Shuler, M. L. (2009) · Lab on a Chip · doi:10.1039/b901377f · Cited by 431
Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor
Davies, N. M., McLachlan, A. J., Day, R. O., & Williams, K. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038030-00003 · Cited by 424
Shah, D. K., & Betts, A. M. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-011-9232-2 · Cited by 422
Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes
Rodgers, T., & Rowland, M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9210-3 · Cited by 420
“a Values taken from the literature (110,111,112) 924 Rodgers and Rowland”
Expandable gastroretentive dosage forms
Klausner, E. A., Lavy, E., Friedman, M., & Hoffman, A. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00203-7 · Cited by 419
Technical Challenges in Using Human Induced Pluripotent Stem Cells to Model Disease
Saha, K., & Jaenisch, R. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.11.009 · Cited by 411
Swift*, B., Pfeifer*, N. D., & Brouwer, K. L. R. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903491881 · Cited by 365
Cheng, Y.-H., He, C., Riviere, J. E., Monteiro-Riviere, N. A., & Lin, Z. (2020) · ACS Nano · doi:10.1021/acsnano.9b08142 · Cited by 362
Liu, H., Yang, J., Du, F., Gao, X., Ma, X., Huang, Y., Xu, F., Niu, W., Wang, F., Mao, Y., et al. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029819 · Cited by 361
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
Ingelman-Sundberg, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0819-z · Cited by 353
Physiologically Based Pharmacokinetic Modeling of Nanoparticles
Li, M., Al-Jamal, K. T., Kostarelos, K., & Reineke, J. (2010) · ACS Nano · doi:10.1021/nn1018818 · Cited by 351
Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., & Sugiyama, Y. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146647 · Cited by 351
Kumthekar, P., Ko, C. H., Paunesku, T., Dixit, K., Sonabend, A. M., Bloch, O., Tate, M., Schwartz, M., Zuckerman, L., Lezon, R., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3945 · Cited by 345
Ballesta, A., Innominato, P. F., Dallmann, R., Rand, D. A., & Lévi, F. A. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013441 · Cited by 339
Mita, A. C., Denis, L. J., Rowinsky, E. K., DeBono, J. S., Goetz, A. D., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0596 · Cited by 332
Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.3.828-833.2002 · Cited by 319
(2001) · PubMed · Cited by 316
Remsberg, C. M., Yáñez, J. A., Ohgami, Y., Vega‐Villa, K. R., Rimando, A. M., & Davies, N. M. (2008) · Phytotherapy Research · doi:10.1002/ptr.2277 · Cited by 314
Scaling and systems biology for integrating multiple organs-on-a-chip
Wikswo, J. P., Curtis, E. L., Eagleton, Z. E., Evans, B. C., Kole, A., Hofmeister, L. H., & Matloff, W. J. (2013) · Lab on a Chip · doi:10.1039/c3lc50243k · Cited by 309
Chapter 33. Plasma Protein Binding of Drugs
Olson, R. E., & Christ, D. D. (1996) · Annual Reports in Medicinal Chemistry · doi:10.1016/s0065-7743(08)60472-8 · Cited by 303
httk: R Package for High-Throughput Toxicokinetics
Pearce, R. G., Setzer, R. W., Strope, C. L., Sipes, N. S., & Wambaugh, J. F. (2017) · Journal of Statistical Software · doi:10.18637/jss.v079.i04 · Cited by 298
Oyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.002 · Cited by 296
Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides
Qian, Z., Martyna, A., Hard, R. L., Wang, J., Appiah-Kubi, G., Coss, C., Phelps, M. A., Rossman, J. S., & Pei, D. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00226 · Cited by 296
Whole Body Pharmacokinetic Models
Nestorov, I. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342100-00002 · Cited by 290
Gourdeau, H., Leblond, L., Hamelin, B., Desputeau, C., Dong, K., Kianicka, I., Custeau, D., Boudreau, C., Geerts, L., Cai, S.-X., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1375.3.11 · Cited by 290
Paulson, S. K., Vaughn, M. B., Jessen, S. M., Lawal, Y., Gresk, C. J., Yan, B., Maziasz, T. J., Cook, C. S., & Karim, A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29580-x · Cited by 289
Coteron, J. M., Marco, M., Esquivias, J., Deng, X., White, K. L., White, J., Koltun, M., El Mazouni, F., Kokkonda, S., Katneni, K., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200592f · Cited by 287
Gilbert, J. C., DeFeo-Fraulini, T., Hutabarat, R. M., Horvath, C. J., Merlino, P. G., Marsh, H. N., Healy, J. M., BouFakhreddine, S., Holohan, T. V., & Schaub, R. G. (2007) · Circulation · doi:10.1161/circulationaha.107.724864 · Cited by 286
Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285
Esch, M. B., Mahler, G. J., Stokol, T., & Shuler, M. L. (2014) · Lab Chip · doi:10.1039/c4lc00371c · Cited by 281
Takano, R., Sugano, K., Higashida, A., Hayashi, Y., Machida, M., Aso, Y., & Yamashita, S. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0162-4 · Cited by 281
Sjögren, E., Abrahamsson, B., Augustijns, P., Becker, D., Bolger, M. B., Brewster, M., Brouwers, J., Flanagan, T., Harwood, M., Heinen, C., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.010 · Cited by 279
Flavonoid–drug interactions: Effects of flavonoids on ABC transporters
Morris, M. E., & Zhang, S. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.003 · Cited by 273
Brain uptake of thiamine-coated nanoparticles
Lockman, P. R., Oyewumi, M. O., Koziara, J. M., Roder, K. E., Mumper, R. J., & Allen, D. D. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.006 · Cited by 259
New developments for antibody-drug conjugate-based therapeutic approaches
de Goeij, B. E., & Lambert, J. M. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.008 · Cited by 256
Lin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
Ward, K. W., & Smith, B. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.6.603 · Cited by 212
Ring, B. J., Chien, J. Y., Adkison, K. K., Jones, H. M., Rowland, M., Jones, R. D., Yates, J. W. T., Ku, M. S., Gibson, C. R., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22552 · Cited by 206
PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals
Bois, F. Y., Jamei, M., & Clewell, H. J. (2010) · Toxicology · doi:10.1016/j.tox.2010.06.007 · Cited by 194
Poulin, P., Jones, R. D. O., Jones, H. M., Gibson, C. R., Rowland, M., Chien, J. Y., Ring, B. J., Adkison, K. K., Ku, M. S., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22550 · Cited by 174
Zheng, Y., Tesar, D. B., Benincosa, L., Birnböck, H., Boswell, C. A., Bumbaca, D., Cowan, K. J., Danilenko, D. M., Daugherty, A. L., Fielder, P. J., et al. (2012) · mAbs · doi:10.4161/mabs.4.2.19387 · Cited by 149
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144
“Table III summarizes the mean values of BW, BRW, and MLP for adult animals used for mAb CL prediction.(23,49,50) ABX-IL8 binds to soluble IL-8, and Ab-01 and Ab-02 target soluble IL-13, whereas SGN-40 targets the membrane-bound receptor CD40.”
MethodMiller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142
Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages
Loccisano, A. E., Longnecker, M. P., Campbell, J. L., Andersen, M. E., & Clewell, H. J. (2013) · Journal of Toxicology and Environmental Health, Part A · doi:10.1080/15287394.2012.722523 · Cited by 141
Multi-omic rejuvenation and lifespan extension on exposure to youthful circulation
Zhang, B., Lee, D. E., Trapp, A., Tyshkovskiy, A., Lu, A. T., Bareja, A., Kerepesi, C., McKay, L. K., Shindyapina, A. V., Dmitriev, S. E., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00451-9 · Cited by 134
Mathialagan, S., Piotrowski, M. A., Tess, D. A., Feng, B., Litchfield, J., & Varma, M. V. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074294 · Cited by 128
Distribution kinetics of a micelle-forming block copolymer Pluronic P85
Batrakova, E. V., Li, S., Li, Y., Alakhov, V. Y., Elmquist, W. F., & Kabanov, A. V. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.09.002 · Cited by 121
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
Jumbe, N. L., Xin, Y., Leipold, D. D., Crocker, L., Dugger, D., Mai, E., Sliwkowski, M. X., Fielder, P. J., & Tibbitts, J. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9156-2 · Cited by 119
Hall, C., Lueshen, E., Mošat', A., & Linninger, A. A. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22811 · Cited by 109
Nakamichi, N., Nakayama, K., Ishimoto, T., Masuo, Y., Wakayama, T., Sekiguchi, H., Sutoh, K., Usumi, K., Iseki, S., & Kato, Y. (2016) · Brain and Behavior · doi:10.1002/brb3.477 · Cited by 107
Bisphenol A interferes with synaptic remodeling
Hajszan, T., & Leranth, C. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.06.004 · Cited by 101
Huh, Y., Smith, D. E., & Rose Feng, M. (2011) · Xenobiotica · doi:10.3109/00498254.2011.598582 · Cited by 98
“…flow (LBF) with the following equation as proposed by Ward and Smith (Ward and Smith, 2004): Clearance Clearance LBF LBFhuman animal human animal= ( / ) (2) LBF values used for mouse, rat, dog, monkey and human were 90.0, 55.2, 30.9, 43.6 and 20.7 mL/min/ kg, respectively (Davies and Morris, 1993).”
MethodInfluentialPharmacokinetics of sodium nitrite-induced methemoglobinemia in the rat
Kohn, M. C., Melnick, R. L., Ye, F., & Portier, C. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.6.676 · Cited by 98
“The plasma volume, 2.97% of body weight (Delp et al., 1991; Davies and Morris, 1993), is 3.3 times the volume of the stomach lumen, 0.91% of body weight (Roth et al., 1993).”
BackgroundInfluentialChou, W.-C., & Lin, Z. (2019) · Environment International · doi:10.1016/j.envint.2019.03.058 · Cited by 98
Nagilla, R., & Ward, K. W. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20169 · Cited by 96
A Comparison of Pharmacokinetics between Humans and Monkeys
Akabane, T., Tabata, K., Kadono, K., Sakuda, S., Terashita, S., & Teramura, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028829 · Cited by 97
Zou, P., Chen, H., Paholak, H. J., & Sun, D. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4002393 · Cited by 88
Choi, G.-W., Lee, Y.-B., & Cho, H.-Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11040168 · Cited by 79
“44 in humans [35] and CRBC refers to the drug concentration in red blood cells.”
BackgroundResultDalton, J. T., Yates, C. R., Yin, D., Straughn, A., Marcus, S. L., Golub, A. L., & Meyer, M. C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.507 · Cited by 75
Fielding, R. M., Lewis, R. O., & Moon-McDermott, L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011925132473 · Cited by 72
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
Sharma, R. P., Schuhmacher, M., & Kumar, V. (2018) · Science of The Total Environment · doi:10.1016/j.scitotenv.2017.12.023 · Cited by 68
Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery
Gobeau, N., Stringer, R., De Buck, S., Tuntland, T., & Faller, B. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1951-z · Cited by 67
Sung, J. H., Wang, Y., & Shuler, M. L. (2019) · APL Bioengineering · doi:10.1063/1.5097675 · Cited by 66
Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
“The clearance of (2R,6R)-HNK was higher in mice (51–74 mL/min/ kg) than in rats and dogs (27 and 21 mL/min/kg, respectively), consistent with the higher rates of hepatic blood flow in mice (approximately 2–3-fold higher in mice relative to rats and dogs; Davies and Morris, 1993).”
Interspecies scaling of biliary excreted drugs
Mahmood, I., & Sahajwalla, C. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10174 · Cited by 62
Dawson, D. E., Lau, C., Pradeep, P., Sayre, R. R., Judson, R. S., Tornero-Velez, R., & Wambaugh, J. F. (2023) · Toxics · doi:10.3390/toxics11020098 · Cited by 56
Kadono, K., Akabane, T., Tabata, K., Gato, K., Terashita, S., & Teramura, T. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029322 · Cited by 52
De Bruyn, T., Ufuk, A., Cantrill, C., Kosa, R. E., Bi, Y.-A., Niosi, M., Modi, S., Rodrigues, A. D., Tremaine, L. M., Varma, M. V. S., et al. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.081315 · Cited by 53
Systems Biology, Systems Medicine, Systems Pharmacology: The What and The Why
Stéphanou, A., Fanchon, E., Innominato, P. F., & Ballesta, A. (2018) · Acta Biotheoretica · doi:10.1007/s10441-018-9330-2 · Cited by 50
Haraya, K., Tachibana, T., & Nezu, J. (2017) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.05.002 · Cited by 43
Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.11.2836 · Cited by 41
Marcyk, P. T., LeBlanc, E. V., Kuntz, D. A., Xue, A., Ortiz, F., Trilles, R., Bengtson, S., Kenney, T. M. G., Huang, D. S., Robbins, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01777 · Cited by 40
Trevaskis, N. L., Lee, G., Escott, A., Phang, K. L., Hong, J., Cao, E., Katneni, K., Charman, S. A., Han, S., Charman, W. N., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00458 · Cited by 39
“…portal blood flow rate [taken from published data for mice (Xie et al., 2014), rats (Mansbach et al., 1991), dogs (Frink et al., 1992), and humans (Davies and Morris, 1993)] is not constant across species (i.e., E 6= 0) but rather increases with species body mass and scales allometrically with…”
BackgroundInfluentialUrayama, A., Moreno-Gonzalez, I., Morales-Scheihing, D., Kharat, V., Pritzkow, S., & Soto, C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01679-4 · Cited by 37
Metadata
- Authors
- Davies, B., & Morris, T.
- Venue
- Pharmaceutical Research
- Published
- 1993-07
- Volume
- 10
- Issue
- 7
- Pages
- 1093-1095
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W152943885
- Cited by
- 2,926
- References
- 0
- FWCI
- 18.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.